Uploaded March 2026 | Updated September 2026, 2 weeks ago
This session provides an in-depth review of recent advances in the management of myasthenia gravis (MG), focusing on evolving treatment paradigms and emerging targeted therapies. Key topics include the role of complement and FcRn inhibitors, B-cell–directed strategies, and novel approaches such as CAR-T cell therapy. The presentation will examine clinical trial data, therapeutic mechanisms, and practical considerations for integrating these options into individualized care. Attendees will gain insight into optimizing outcomes, achieving minimal manifestation status, and navigating the expanding therapeutic landscape for MG.
This session provides an in-depth review of recent advances in the management of myasthenia gravis (MG), focusing on evolving treatment paradigms and emerging targeted therapies. Key topics include the role of complement and FcRn inhibitors, B-cell–directed strategies, and novel approaches such as CAR-T cell therapy. The presentation will examine clinical trial data, therapeutic mechanisms, and practical considerations for integrating these options into individualized care. Attendees will gain insight into optimizing outcomes, achieving minimal manifestation status, and navigating the expanding therapeutic landscape for MG.
